Aprotinin and renal dysfunction after pediatric cardiac surgery

Andrea Székely, Erzsébet SÁpi, Tamás Breuer, M. Kertai, Gábor Bodor, Péter Vargha, A. Szatmári

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Aprotinin is a potent antifibrinolytic drug, which reduces postoperative bleeding and transfusion requirements. Recently, two observational studies reported increased incidence of renal dysfunction after aprotinin use in adults. Therefore, the aim of the study was to investigate the safety of aprotinin use in pediatric cardiac surgery patients. Methods: Data were prospectively and consecutively collected from 657 pediatric patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). The database was assessed with regard to a possible relationship between aprotinin administration and dialysis and between aprotinin and postoperative renal dysfunction [defined as 25% decrease in the creatinine clearance (Ccr) compared with the preoperative value] by propensity-score adjustment and multivariable methods. Results: The incidence of dialysis (9.6% vs 4.1%; P = 0.005) and renal dysfunction (26.3% vs 16.1%; P = 0.019) was higher in patients who received aprotinin; however, propensity adjusted risk ratios were not significant [odds ratio (OR) of dialysis: 1.22; 95% confidence interval (CI) 0.46-3.22; OR of renal dysfunction 1.26; 95% CI: 0.66-1.92]. Aprotinin significantly reduced blood loss in the first postoperative 24 h. The main contributors of renal dysfunction were CPB duration, cumulative inotropic support, age, preoperative Ccr, amount of transfusion and pulmonary hypertension. Conclusions: Despite the higher incidences of renal dysfunction and failure in the aprotinin group, an independent role of the drug in the development of renal dysfunction or dialysis could not be demonstrated in pediatric cardiac patients undergoing CPB.

Original languageEnglish
Pages (from-to)151-159
Number of pages9
JournalPaediatric Anaesthesia
Volume18
Issue number2
DOIs
Publication statusPublished - Feb 2008

Fingerprint

Aprotinin
Thoracic Surgery
Pediatrics
Kidney
Dialysis
Cardiopulmonary Bypass
Odds Ratio
Creatinine
Incidence
Confidence Intervals
Propensity Score
Antifibrinolytic Agents
Pulmonary Hypertension
Pharmaceutical Preparations
Observational Studies
Renal Insufficiency
Databases
Hemorrhage
Safety

Keywords

  • Aprotinin
  • Congenital heart disease
  • Congenital heart surgery
  • Dialysis
  • Pediatric cardiac surgery
  • Pediatrics
  • Predictors
  • Renal function
  • Risk factors
  • Transfusion

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Aprotinin and renal dysfunction after pediatric cardiac surgery. / Székely, Andrea; SÁpi, Erzsébet; Breuer, Tamás; Kertai, M.; Bodor, Gábor; Vargha, Péter; Szatmári, A.

In: Paediatric Anaesthesia, Vol. 18, No. 2, 02.2008, p. 151-159.

Research output: Contribution to journalArticle

Székely, Andrea ; SÁpi, Erzsébet ; Breuer, Tamás ; Kertai, M. ; Bodor, Gábor ; Vargha, Péter ; Szatmári, A. / Aprotinin and renal dysfunction after pediatric cardiac surgery. In: Paediatric Anaesthesia. 2008 ; Vol. 18, No. 2. pp. 151-159.
@article{124e83d78d5c4a6fa102361a8c894fa5,
title = "Aprotinin and renal dysfunction after pediatric cardiac surgery",
abstract = "Background: Aprotinin is a potent antifibrinolytic drug, which reduces postoperative bleeding and transfusion requirements. Recently, two observational studies reported increased incidence of renal dysfunction after aprotinin use in adults. Therefore, the aim of the study was to investigate the safety of aprotinin use in pediatric cardiac surgery patients. Methods: Data were prospectively and consecutively collected from 657 pediatric patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). The database was assessed with regard to a possible relationship between aprotinin administration and dialysis and between aprotinin and postoperative renal dysfunction [defined as 25{\%} decrease in the creatinine clearance (Ccr) compared with the preoperative value] by propensity-score adjustment and multivariable methods. Results: The incidence of dialysis (9.6{\%} vs 4.1{\%}; P = 0.005) and renal dysfunction (26.3{\%} vs 16.1{\%}; P = 0.019) was higher in patients who received aprotinin; however, propensity adjusted risk ratios were not significant [odds ratio (OR) of dialysis: 1.22; 95{\%} confidence interval (CI) 0.46-3.22; OR of renal dysfunction 1.26; 95{\%} CI: 0.66-1.92]. Aprotinin significantly reduced blood loss in the first postoperative 24 h. The main contributors of renal dysfunction were CPB duration, cumulative inotropic support, age, preoperative Ccr, amount of transfusion and pulmonary hypertension. Conclusions: Despite the higher incidences of renal dysfunction and failure in the aprotinin group, an independent role of the drug in the development of renal dysfunction or dialysis could not be demonstrated in pediatric cardiac patients undergoing CPB.",
keywords = "Aprotinin, Congenital heart disease, Congenital heart surgery, Dialysis, Pediatric cardiac surgery, Pediatrics, Predictors, Renal function, Risk factors, Transfusion",
author = "Andrea Sz{\'e}kely and Erzs{\'e}bet S{\'A}pi and Tam{\'a}s Breuer and M. Kertai and G{\'a}bor Bodor and P{\'e}ter Vargha and A. Szatm{\'a}ri",
year = "2008",
month = "2",
doi = "10.1111/j.1460-9592.2007.02398.x",
language = "English",
volume = "18",
pages = "151--159",
journal = "Paediatric Anaesthesia",
issn = "1155-5645",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Aprotinin and renal dysfunction after pediatric cardiac surgery

AU - Székely, Andrea

AU - SÁpi, Erzsébet

AU - Breuer, Tamás

AU - Kertai, M.

AU - Bodor, Gábor

AU - Vargha, Péter

AU - Szatmári, A.

PY - 2008/2

Y1 - 2008/2

N2 - Background: Aprotinin is a potent antifibrinolytic drug, which reduces postoperative bleeding and transfusion requirements. Recently, two observational studies reported increased incidence of renal dysfunction after aprotinin use in adults. Therefore, the aim of the study was to investigate the safety of aprotinin use in pediatric cardiac surgery patients. Methods: Data were prospectively and consecutively collected from 657 pediatric patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). The database was assessed with regard to a possible relationship between aprotinin administration and dialysis and between aprotinin and postoperative renal dysfunction [defined as 25% decrease in the creatinine clearance (Ccr) compared with the preoperative value] by propensity-score adjustment and multivariable methods. Results: The incidence of dialysis (9.6% vs 4.1%; P = 0.005) and renal dysfunction (26.3% vs 16.1%; P = 0.019) was higher in patients who received aprotinin; however, propensity adjusted risk ratios were not significant [odds ratio (OR) of dialysis: 1.22; 95% confidence interval (CI) 0.46-3.22; OR of renal dysfunction 1.26; 95% CI: 0.66-1.92]. Aprotinin significantly reduced blood loss in the first postoperative 24 h. The main contributors of renal dysfunction were CPB duration, cumulative inotropic support, age, preoperative Ccr, amount of transfusion and pulmonary hypertension. Conclusions: Despite the higher incidences of renal dysfunction and failure in the aprotinin group, an independent role of the drug in the development of renal dysfunction or dialysis could not be demonstrated in pediatric cardiac patients undergoing CPB.

AB - Background: Aprotinin is a potent antifibrinolytic drug, which reduces postoperative bleeding and transfusion requirements. Recently, two observational studies reported increased incidence of renal dysfunction after aprotinin use in adults. Therefore, the aim of the study was to investigate the safety of aprotinin use in pediatric cardiac surgery patients. Methods: Data were prospectively and consecutively collected from 657 pediatric patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). The database was assessed with regard to a possible relationship between aprotinin administration and dialysis and between aprotinin and postoperative renal dysfunction [defined as 25% decrease in the creatinine clearance (Ccr) compared with the preoperative value] by propensity-score adjustment and multivariable methods. Results: The incidence of dialysis (9.6% vs 4.1%; P = 0.005) and renal dysfunction (26.3% vs 16.1%; P = 0.019) was higher in patients who received aprotinin; however, propensity adjusted risk ratios were not significant [odds ratio (OR) of dialysis: 1.22; 95% confidence interval (CI) 0.46-3.22; OR of renal dysfunction 1.26; 95% CI: 0.66-1.92]. Aprotinin significantly reduced blood loss in the first postoperative 24 h. The main contributors of renal dysfunction were CPB duration, cumulative inotropic support, age, preoperative Ccr, amount of transfusion and pulmonary hypertension. Conclusions: Despite the higher incidences of renal dysfunction and failure in the aprotinin group, an independent role of the drug in the development of renal dysfunction or dialysis could not be demonstrated in pediatric cardiac patients undergoing CPB.

KW - Aprotinin

KW - Congenital heart disease

KW - Congenital heart surgery

KW - Dialysis

KW - Pediatric cardiac surgery

KW - Pediatrics

KW - Predictors

KW - Renal function

KW - Risk factors

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=37749042740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37749042740&partnerID=8YFLogxK

U2 - 10.1111/j.1460-9592.2007.02398.x

DO - 10.1111/j.1460-9592.2007.02398.x

M3 - Article

C2 - 18184247

AN - SCOPUS:37749042740

VL - 18

SP - 151

EP - 159

JO - Paediatric Anaesthesia

JF - Paediatric Anaesthesia

SN - 1155-5645

IS - 2

ER -